Aurobindo Pharma’s CuraTeQ Gets EU Approval for Cancer Biosimilar Dazublys™

Aurobindo Pharma Limited has announced a significant milestone: its wholly owned step-down subsidiary, **CuraTeQ Biologics s.r.o.**, has received **marketing authorization from the European Commission** for **Dazublys™**, a biosimilar of trastuzumab, used in treating HER2-positive breast and gastric cancers. This regulatory green light follows a **positive recommendation by the European Medicines Agency (EMA)** in April 2025. Dazublys™ becomes CuraTeQ’s **third biosimilar approved by EMA in 2025**, after **Dyrupeg™ (April)** and **Zefylti™ (February)**. It also marks CuraTeQ’s **fourth biosimilar approval in the EU market**, with **Bevqolva™** having received clearance from the UK’s MHRA in December 2024. This consistent progress highlights Aurobindo Pharma’s expanding footprint in the global biologics segment and strengthens its oncology-focused biosimilar portfolio in regulated markets. Investors and healthcare stakeholders are likely to view this development as a strategic boost to the company's long-term growth trajectory in the high-value biosimilar space.